The short interest in Rockwell Medical, Inc. (NASDAQ:RMTI) has increased from 11,025,579 on May 15,2015 to 11,430,065 on May 29,2015. The change was measured at 404,486 shares or 3.7%. The leftover shorts were 24.3% of the floated shares. The days to cover are 26, given the average daily volume of 446,323 shares. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 8th.

Many Wall Street Brokerage firms have commented on company shares. Oppenheimer initiates coverage on Rockwell Medical, Inc. (NASDAQ:RMTI) In a research note issued to the investors, the brokerage major a price-target of $24 per share.The shares have been rated Outperform.

Rockwell Medical, Inc. (NASDAQ:RMTI) : On Tuesday heightened volatility was witnessed in Rockwell Medical, Inc. (NASDAQ:RMTI) which led to swings in the share price. The shares opened for trading at $12.61 and hit $12.9399 on the upside , eventually ending the session at $12.66, with a gain of 0.88% or 0.11 points. The heightened volatility saw the trading volume jump to 921,363 shares. The 52-week high of the share price is $12.6 and the company has a market cap of $635 million. The 52-week low of the share price is at $8.095 .

The company shares have rallied 14.82% from its one year high price. On June 8, 2015 The shares registered one year high of $12.6 and one year low was seen on December 15, 2014 at $8.1. The 50-day moving average is $10.48 and the 200 day moving average is recorded at $10.2. S&P 500 has rallied 6.59% during the last 52-weeks.

Rockwell Medical, Inc., formerly Rockwell Medical Technologies, Inc., manufactures hemodialysis concentrate solutions and dialysis kits, and it sells, distributes and delivers these and other ancillary hemodialysis products primarily to hemodialysis providers in the United States, as well as internationally primarily in Asia, Latin America and Europe. Hemodialysis duplicates kidney function in patients with failing kidneys also known as End Stage Renal Disease (ESRD). ESRD is an advanced-stage of chronic kidney disease (CKD) characterized by the irreversible loss of kidney function. Its dialysis solutions (also known as dialysate) are used to maintain life, removing toxins and replacing nutrients in the dialysis patients bloodstream. As of December 31, 2011, it was licensed and was developing renal drug therapies. During the year ended December 31, 2011, it acquired an abbreviated new drug application (ANDA) for a generic version of an intravenous Vitamin-D analogue, calcitriol.

...